The early‐stage clinical course of anti‐pituitary‐specific transcription factor‐1 hypophysitis diagnosed post‐immune checkpoint inhibitor treatment: A case with review of literature

Abstract

AbstractAnti‐pituitary‐specific transcription factor‐1 (PIT‐1) hypophysitis, a paraneoplastic syndrome resulting from an autoimmune response against PIT‐1, typically manifests with undetectable levels of growth hormone (GH) and prolactin (PRL), and significantly low levels of serum thyroid‐stimulating hormone (TSH) at diagnosis. These hormonal levels are highly specific to this disease and serve as key diagnostic indicators. Herein, we present a detailed clinical course of a 69‐year‐old male with a history of gastric cancer and lymph node metastases who developed anti‐PIT‐1 hypophysitis after the initiation of immune checkpoint inhibitor (ICI) therapy, specifically nivolumab, oxaliplatin, and capecitabine. The patient was referred to our department owing to decreased TSH, free triiodothyronine (T3), and free thyroxine (T4) levels after two doses of nivolumab. Initially suspected as central hypothyroidism due to ICI‐related hypophysitis, further assessment confirmed the diagnosis of anti‐PIT‐1 hypophysitis. Notably, GH, PRL, and TSH levels markedly declined, leading to complete deficiencies 2 months after the first nivolumab dose—a pattern consistent with that of previous cases of anti‐PIT‐1 hypophysitis. Therefore, this report not only presents an atypical subset of ICI‐related hypophysitis but also delineates the process of hormone impairment leading to complete deficiencies in anti‐PIT‐1 hypophysitis. This case highlights the importance of vigilant monitoring for endocrine issues in patients undergoing ICI therapy, given the escalating incidence of immune‐related adverse events associated with the extensive use of ICI therapy for various cancers.